Back to top
more

Better trading starts here.

Brokerage Reports

Research for ACAD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

2 items in cart

View Cart/Checkout

ACADIA Pharmaceuticals Inc. [ACAD]

Reports for Purchase

Showing records 181 - 200 ( 246 total )

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 181

03/03/2015

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 182

02/27/2015

Company Report

Pages: 7

Nuplazid Development Proceeding According to Plan; Reit Buy and $50 PT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 183

02/24/2015

Company Report

Pages: 30

Here''s Lookin'' at You, Nuplazid: Initiating with a Buy Rating and $50 PT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 184

02/18/2015

Industry Report

Pages: 4

Healthcare - Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 185

02/06/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 186

02/05/2015

Company Report

Pages: 12

We resume coverage of Acadia with a Buy rating and $42 PT

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 187

11/25/2014

Industry Report

Pages: 4

CTAD?14: A Renewed Focus Toward the Development of Symptomatic Agents, and our Award for Preclinical ''''One to Watch''''

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 188

08/05/2014

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 189

05/07/2014

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 190

04/16/2014

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 191

02/28/2014

Company Report

Pages: 5

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 192

02/26/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 193

01/22/2014

Company Report

Pages: 5

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 194

11/07/2013

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 195

08/08/2013

Company Report

Pages: 11

2Q - Spending Up as Programs Advance

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 196

08/07/2013

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 197

05/13/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 198

05/13/2013

Company Report

Pages: 11

Looking Toward the NDA, Marketing

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 199

05/07/2013

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 200

04/12/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party